Interleukin-17 potently increases non-small cell lung cancer growth

Wei,Lei; Wang,Hui; Yang,Fen; Ding,Qi; Zhao,Jianhua

doi:10.3892/mmr.2015.4694

Interleukin-17 potently increases non-small cell lung cancer growth

Authors:
- Lei Wei
- Hui Wang
- Fen Yang
- Qi Ding
- Jianhua Zhao
View Affiliations

Affiliations: Department of Anesthesiology, Suzhou Municipal Hospital Affiliated to Nanjing Medical University, Suzhou, Jiangsu 215002, P.R. China
Published online on: December 18, 2015 https://doi.org/10.3892/mmr.2015.4694
Pages: 1673-1680

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to explore the effects of interleukin (IL)-17 on the growth and metastasis of tumors that were subcutaneously implanted into C57BL/6 mice. Lewis lung carcinoma (LLC) cells were subcutaneously injected into C57BL/6 mice followed by intraperitoneal injection of mouse recombinant IL-17 protein (IL-17 groups) or phosphate‑buffered saline (control groups). Tumor growth and metastasis were assessed by measuring the size and weight of tumors and cervical lymph nodes, respectively. Cytokine expression in tumor masses was quantified by reverse transcription‑quantitative polymerase chain reaction and western blotting, respectively. CCR2‑positive macrophage infiltration in tumor masses was detected by flow cytometric analysis. The proliferation and migration of LLC cells, stimulated by the IL-17 protein were detected by Cell Counting kit (CCK)‑8 and wound scratch assays in vitro. Tumors were grafted into the C57BL/6 mice. The mice that were intraperitoneally injected with IL-17 exhibited significantly larger tumors compared with the control mice. After day 7 of injection and beyond, the weight of cervical lymph nodes in IL-17 groups was higher than that in the control mice. It was also demonstrated that the number of CCR2-positive macrophages that infiltrated the tumor masses in the IL-17 groups was higher than that of the control mice. CD34 expression in vascular endothelial cells was also higher in tumors grafted in IL-17 mice than those grafted in control mice. Furthermore, the tumor tissue mRNA and protein expression levels of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, MMP-9 and tumor necrosis factor-α were greater in mice from the IL-17 group than the control mice, while levels of migration inhibitory factor and thrombospondin‑1 were lower in mice from the IL-17 group than in the control. IL-17 also increased the migration of LLC cells in vitro. In conclusion, IL-17 exhibited the ability to promote tumor growth by increasing angiogenesis, metastasis and increasing CCR2+ macrophage infiltration into tumors.

View Figures

View References

1	Machtay M and Jeremic B: Complex and controversial issues in locally advanced non-small cell lung carcinoma. Semin Surg Oncol. 21:128–137. 2003. View Article : Google Scholar : PubMed/NCBI
2	Stanley K and Stjernswärd J: Lung cancer-a worldwide health problem. Chest. 96(Suppl 1): S1–S5. 1989. View Article : Google Scholar
3	Thatcher N: New perspectives in lung cancer. 4 Haematopoietic growth factors and lung cancer treatment. Thorax. 47:119–126. 1992. View Article : Google Scholar : PubMed/NCBI
4	Weynants P, Marchandise FX and Sibille Y: Pulmonary perspective: Immunology in diagnosis and treatment of lung cancer. Eur Respir J. 10:1703–1719. 1997. View Article : Google Scholar : PubMed/NCBI
5	Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, Cohen JI and Spriggs MK: Herpes virus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity. 3:811–821. 1995. View Article : Google Scholar : PubMed/NCBI
6	Starnes T, Robertson MJ, Sledge G, Kelich S, Nakshatri H, Broxmeyer HE and Hromas R: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J Immunol. 167:4137–4140. 2001. View Article : Google Scholar : PubMed/NCBI
7	Hymowitz SG, Filvaroff EH, Yin JP, Lee J, Cai L, Risser P, Maruoka M, Mao W, Foster J, Kelley RF, et al: IL-17s adopt a cystine knot fold: Structure and activity of a novel cytokine, IL-17F and implications for receptor binding. EMBO J. 20:5332–5341. 2001. View Article : Google Scholar : PubMed/NCBI
8	Antonysamy MA and Numasaki M: Interleukin-17 (IL-17, IL-25) In The Cytokine Handbook, 4th Ed A W Thomson and M T Lotze, eds. Academic Press; London: pp. 475–502. 2003
9	Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ, Garrone P, Garcia E, Saeland S, et al: T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med. 183:2593–2603. 1996. View Article : Google Scholar : PubMed/NCBI
10	Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK and Armitage RJ: Human IL-17: A novel cytokine derived from T cells. J Immunol. 155:5483–5486. 1995.PubMed/NCBI
11	Numasaki M, Tomioka Y, Takahashi H and Sasaki H: IL-17 and IL-17F modulate GM-CSF production by lung microvascular endothelial cells stimulated with IL-1beta and/or TNF-alpha. Immunol Lett. 95:175–184. 2004. View Article : Google Scholar : PubMed/NCBI
12	Numasaki M, Takahashi H, Tomioka Y and Sasaki H: Regulatory roles of IL-17 and IL-17F in G-CSF production by lung microvascular endothelial cells stimulated with IL-1beta and/or TNF-alpha. Immunol Lett. 95:97–104. 2004. View Article : Google Scholar : PubMed/NCBI
13	Numasaki M, Lotze MT and Sasaki H: Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett. 93:39–43. 2004. View Article : Google Scholar : PubMed/NCBI
14	Aarvak T, Chabaud M, Miossec P and Natvig JB: IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol. 162:1246–1251. 1999.PubMed/NCBI
15	Yao Z, Spriggs MK, Derry JM, Strockbine L, Park LS, VandenBos T, Zappone JD, Painter SL and Armitage RJ: Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine. 9:794–800. 1997. View Article : Google Scholar
16	Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, et al: IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastgenesis. J Clin Invest. 103:1345–1352. 1999. View Article : Google Scholar : PubMed/NCBI
17	Chabaud M, Lubberts E, Joosten L, van Den Berg W and Miossec P: IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res. 3:168–177. 2001. View Article : Google Scholar : PubMed/NCBI
18	Antonysamy MA, Fanslow WC, Fu F, Li W, Qian S, Troutt AB and Thomson AW: Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol. 162:577–584. 1999.PubMed/NCBI
19	Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA and Bos JD: Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol. 111:645–649. 1998. View Article : Google Scholar : PubMed/NCBI
20	Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Pagé N, Olivenstein R, Elias J and Chakir J: IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol. 108:430–438. 2001. View Article : Google Scholar : PubMed/NCBI
21	Yang B, Kang H, Fung A, Zhao H, Wang T and Ma D: The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis. Mediators Inflamm. 2014:6237592014. View Article : Google Scholar : PubMed/NCBI
22	Murugaiyan G and Saha B: Protumor vs antitumor functions of IL-17. J Immunol. 183:4169–4175. 2009. View Article : Google Scholar : PubMed/NCBI
23	Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J and Wang RF: Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci USA. 105:15505–15510. 2008. View Article : Google Scholar : PubMed/NCBI
24	Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP and Zheng L: Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol. 50:980–989. 2009. View Article : Google Scholar : PubMed/NCBI
25	Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK and Sasaki H: IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol. 175:6177–6189. 2005. View Article : Google Scholar : PubMed/NCBI
26	Lin L, Chen YS, Yao YD, Chen JQ, Chen JN, Huang SY, Zeng YJ, Yao HR, Zeng SH, Fu YS and Song EW: CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer. Oncotarget. 6:34758–34773. 2015.PubMed/NCBI
27	Dobrzycka B, Mackowiak-Matejczyk B, Kinalski M and Terlikowski SJ: Pretreatment serum levels of bFGF and VEGF and its clinical significance in endometrial carcinoma. Gynecol Oncol. 128:454–460. 2013. View Article : Google Scholar
28	Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q and Dong C: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 6:1133–1141. 2005. View Article : Google Scholar : PubMed/NCBI
29	Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H and Lotze MT: Interleukin-17 promotes angiogenesis and tumor growth. Blood. 101:2620–2627. 2003. View Article : Google Scholar
30	Kato T, Furumoto H, Ogura T, Onishi Y, Irahara M, Yamano S, Kamada M and Aono T: Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Commun. 282:735–738. 2001. View Article : Google Scholar : PubMed/NCBI
31	Reppert S, Boross I, Koslowski M, Türeci Ö, Koch S, Lehr HA and Finotto S: A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer. Nat Commun. 2:6002011. View Article : Google Scholar : PubMed/NCBI
32	Duan MC, Zhong XN, Liu GN and Wei JR: The Treg/Th17 paradigm in lung cancer. J Immunol Res. 2014:7303802014. View Article : Google Scholar : PubMed/NCBI
33	Iida T, Iwahashi M, Katsuda M, Ishida K, Nakamori M, Nakamura M, Naka T, Ojima T, Ueda K, Hayata K, et al: Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer. Oncol Rep. 25:1271–1277. 2011.PubMed/NCBI
34	Chae WJ, Gibson TF, Zelterman D, Hao L, Henegariu O and Bothwell AL: Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc Natl Acad Sci USA. 107:5540–5544. 2010. View Article : Google Scholar : PubMed/NCBI
35	Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty P, Thompson RG, Kollias G, Smyth JF, et al: The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest. 119:3011–3023. 2009. View Article : Google Scholar : PubMed/NCBI
36	Ichinose Y, Yano T, Asoh H, Yokoyama H, Yoshino I and Katsuda Y: Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer. An analysis in each pathologic stage. J Thorac Cardiovasc Surg. 110:601–605. 1995. View Article : Google Scholar : PubMed/NCBI
37	van Velzen E, Snijder RJ, Brutel de la Rivière A, Elbers HJ and van den Bosch JM: Type of lymph node involvement influences survival rates in T1N1M0 non-small cell lung carcinoma. Lymph node involvement by direct extension compared with lobar and hilar node metastases. Chest. 110:1469–1473. 1996. View Article : Google Scholar : PubMed/NCBI
38	Mountain CF and Dresler CM: Regional lymph node classification for lung cancer staging. Chest. 111:1718–1723. 1997. View Article : Google Scholar : PubMed/NCBI
39	Sierra-Filardi E, Nieto C, Domínguez-Soto A, Barroso R, Sánchez-Mateos P, Puig-Kroger A, López-Bravo M, Joven J, Ardavín C, Rodríguez-Fernández JL, et al: CCL2 shapes macrophage polarization by GM-CSF and M-CSF: Identification of CCL2/CCR2-dependent gene expression profile. J Immunol. 192:3858–3867. 2014. View Article : Google Scholar : PubMed/NCBI
40	Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, et al: Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 73:1128–1141. 2013. View Article : Google Scholar :
41	Chen X, Wan J, Liu J, Xie W, Diao X, Xu J, Zhu B and Chen Z: Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer. 69:348–354. 2010. View Article : Google Scholar